Transformation in the use of radiation therapy of Hodgkin lymphoma: New concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT)

Abstract:  The role of radiation therapy (RT) in Hodgkin lymphoma has changed substantially; it has evolved from a first‐line comprehensive single agent into a complementary adjuvant following chemotherapy. Yet, the significant contribution of adding radiotherapy has repeatedly been confirmed by recent information from several prospective randomized trials in early stage patients (CCG, Canada NCIC, and EORTC/GELA H9F). In a recent study that included patients of all stages adding radiotherapy impacted significantly on overall survival. Even in advanced‐stage disease, in patients with less than CR, and/or bulky disease or in programs that use short‐course chemotherapy (e.g. Stanford V) involved‐field radiation therapy (IFRT) remained essential. Randomized studies and most recently the GHSG HD10 and HD11 documented excellent results with low‐dose IFRT of only 20 Gy in both early stage and in intermediate‐stage patients. It is now standard of care to use IFRT rather than the extended radiation fields of the past (mantle, inverted Y, and STLI/TLI). Even smaller volumes than IFRT, such as ‘lymph‐node fields’ are advocated by paediatrics groups and are under consideration for future adults treatment programs. This change in RT concept has been motivated by need to reduce normal tissue exposure in order to markedly lessen the risk of late complications. The small fields of current radiotherapy allow more conformal and innovative approaches that have not been technically feasible in the past. They also mandate better targeting. Both the accuracy and the confirmality of ‘min‐radiation’ are augmented, by using new advances in imaging, treatment planning, and new radiation delivery systems. The PET/CT/Simulator integrated hardware with innovative software allows more accurate PET and CT (or MRI) parallel volume contouring, radiation ‘dose painting’ (dose tailored to PET residual activity) and field ‘sculpting’. Introducing intensity modulated radiotherapy technology (IMRT) – a technology that was originally designed for small tumors treated with very high doses – to the field of lymphoma provides safer and more accurate radiotherapy to selected patients with very bulky residual disease and permits re‐irradiation of relapsed disease.

[1]  V. Devita Hodgkin's disease--clinical trials and travails. , 2003, The New England journal of medicine.

[2]  P. Maslak,et al.  Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Jaffe,et al.  Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Connors,et al.  Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Zelenetz,et al.  A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. , 2001, Blood.

[6]  K. Propert,et al.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.

[7]  P. Gobbi,et al.  ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  G. Papa,et al.  Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  V. Diehl,et al.  Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. , 2003, Hematology. American Society of Hematology. Education Program.

[10]  T. Miller,et al.  Low-Dose Involved Field Radiation after Chemotherapy in Advanced Hodgkin Disease: A Southwest Oncology Group Randomized Study , 1994, Annals of Internal Medicine.

[11]  R. Fisher,et al.  Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Greil,et al.  Reduction of Combined Modality Treatment Intensity in Early Stage Hodgkin’s Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG. , 2004 .

[13]  P. Davis,et al.  Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Naresh,et al.  Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Zelenetz,et al.  Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy‐proven primary refractory Hodgkin's disease , 2004, British journal of haematology.

[16]  A. Hagenbeek,et al.  Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Dirk Hasenclever,et al.  Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Goodman,et al.  Intensity-modulated radiotherapy for lymphoma involving the mediastinum. , 2005, International journal of radiation oncology, biology, physics.

[19]  B. Clarkson,et al.  Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Friedberg,et al.  Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Mauch,et al.  The involved field is back: issues in delineating the radiation field in Hodgkin's disease. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  V. Diehl,et al.  Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  E. Winer,et al.  Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. , 1990, International journal of radiation oncology, biology, physics.

[24]  A. Zelenetz,et al.  Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. , 2004, Blood.

[25]  S. Horning,et al.  Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  V. Diehl,et al.  Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Bonadonna,et al.  ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Ng,et al.  Controversies in early-stage Hodgkin's disease. , 2002, Oncology.

[29]  S. Horning,et al.  High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival. , 1996, International journal of radiation oncology, biology, physics.

[30]  J. Raemaekers,et al.  Involved-field radiotherapy for advanced Hodgkin's lymphoma. , 2003, The New England journal of medicine.

[31]  V. Diehl,et al.  Part II: Hodgkin's lymphoma--diagnosis and treatment. , 2004, The Lancet Oncology.

[32]  R. Greil,et al.  Intensification of Chemotherapy and Concomitant Reduction of Radiotherapy Dose in Intermediate Stage Hodgkin′s Lymphoma: Results of the Fourth Interim Analysis of the HD 11 Trial of the GHSG. , 2004 .

[33]  L. Prosnitz,et al.  The case for adjuvant radiation therapy in advanced Hodgkin's disease. , 1996, Cancer investigation.